As part of an attempt to fight drug-resistant bacteria, U.S. lawmakers have introduced the PASTEUR Act, a bill to support the development of new antibiotics. The new legislation would provide up to $3 billion to drug developers for antibiotics. (STAT)

Novo Nordisk and Lumen Bioscience are setting their sights on obesity and other metabolic disorder treatments. The two companies will collaborate on an oral obesity drug, with initial research expected to take about a year. (Endpoints News)

Regeneron Pharmaceuticals’ COVID-19 antibody therapy was effective in lowering the death rate among hospitalized patients, the company announced. REGEN-COV has received emergency use authorization in the U.S., but the latest trial results are the first to show solid evidence of efficacy. (Reuters)

At the CNBC Evolve Global Summit, Novartis CEO Dr. Vas Narasimhan said additional pandemics are bound to happen in the future. He outlined how policymakers and healthcare providers could prepare moving forward, such as by stocking up on protective gear and improving manufacturing capabilities. (CNBC Weekly)

A national charity will buy $278 million of medical debt directly from hospitals in an effort to help patients bogged down by large medical costs. RIP Medical Debt is partnering with Ballad Health to assist 82,000 low-income patients. (The Wall Street Journal)